Edition:
United States

Pfizer Says FDA Accepts Submissions For Review Of Tafamidis


Monday, 14 Jan 2019 08:00am EST 

Jan 14 (Reuters) - Pfizer Inc ::US FDA ACCEPTS REGULATORY SUBMISSIONS FOR REVIEW OF TAFAMIDIS TO TREAT TRANSTHYRETIN AMYLOID CARDIOMYOPATHY.PFIZER INC - TARGET PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR A DECISION BY FDA IS IN JULY 2019.PFIZER INC - FDA GRANTS A PRIORITY REVIEW BASED ON PHASE 3 ATTR-ACT STUDY FINDINGS IN ATTR-CM.